
Please try another search
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of various therapeutic proteins for the treatment of oncology diseases. It operates through Biopharmaceutical Medicines, Chemical Medicines, and Others segments. The company offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin’s lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and urticaria; Eydenzelt for diabetic macular edema and wet age-related macular degeneration; Steqeyma for psoriasis and inflammatory bowel disease; Stoboclo/Osenvelt for osteoporosis; Avtozma for rheumatoid arthritis and active systemic juvenile idiopathic arthritis; Zymfentra for inflammatory bowel disease; and Regkirona for COVID-19, as well as CT-G07 for HIV/AIDS and Donerion Patch for Alzheimer's dementia symptoms. It is also developing biosimilars, which are in Phase 3 clinical trials include CT-P44 for multiple myeloma, CT-P51 for melanoma and lung cancer, CT-P53 for multiple sclerosis, and CT-P55 for psoriasis, as well as CT-G20 for hypertrophic cardiomyopathy. In addition, the company engages in the wholesale/retail of medicines. The company distributes its products in approximately 100 countries, including the United States and Europe. The company was founded in 2002 and is headquartered in Incheon, South Korea.
Name | Age | Since | Title |
---|---|---|---|
Wonkyung Choi | - | 2023 | Independent Director |
Jung-Jin Seo | 68 | 2002 | Inside Co-Chairman of the Board |
Hyong-Gi Kim | 60 | 2014 | CEO & Internal Director |
Woo-Sung Kee | 64 | 2014 | Co-CEO & Internal Director |
Jae-sik Lee | - | 2022 | Independent Director |
Young-hyeh Ko | - | 2022 | Independent Director |
Keun-young Kim | - | 2022 | Independent Director |
Byung-oh Kwon | - | - | Director |
Dae-hyun Yoo | - | 2022 | Independent Director |
Soon-Woo Lee | 75 | 2022 | Independent Director |
Jongmoon Choi | - | 2023 | Independent Director |
Jin-seok Seo | - | 2021 | Co-CEO & Inside Co-Chairman of the Board |
Joong Jae Lee | - | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review